Cardiac Insight, a University of Washington spinoff focused on developing advanced body-worn sensing for diagnostic testing in cardiology has raised $2.5 million in Series C funding. The company will utilize the funding to accelerate the market penetration of it’s CardeaScreen™ product as well as finalize the development of the company’s proprietary wearable sensor technology.
Cardea’s flagship product is the CardeaScreen, is a 12-lead electrocardiogram (ECG) exam that helps identify young athletes who may be at risk for sudden cardiac arrest (SCA) in less than 20 seconds. The hand-held device and advanced analysis software then assists physicians to determine the need for further evaluation prior to participation in strenuous activities.
CardeaScreen diagnostic algorithms have substantially reduced the rate of false positive indications. This breakthrough makes the non-invasive screening cost-effective for schools and is emerging as a best practice for pre-participation examinations by pediatricians and family practice physicians.
The company acquired cardiovascular diagnostic developer Cardea Associates for an undisclosed amount last fall. Cardiac Insight raised $7 million in a funding led by Welch Allyn which included a strategic partnership deal with the startup. Cardiac Insight has raised $12.41 million in total funding to date.
